Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
390 Leser
Artikel bewerten:
(2)

International Bureau of Fiscal Documentation (IBFD): Jennifer Roeleveld Will Be the 10th IBFD Professor in Residence

Finanznachrichten News

AMSTERDAM, Jan. 06, 2023 (GLOBE NEWSWIRE) -- IBFD is pleased to announce it has named Jennifer Roeleveld, Emeritus Professor at the University of Cape Town (South Africa) its 2023 Professor in Residence. She will be the first African woman (and the 4th woman out of 10 professors holding that position) to hold this prestigious professorial fellowship.

IBFD is proud of establishing an even closer association with Prof. Roeleveld, who has developed a very productive academic partnership with IBFD during the past decade. The academic synergies between IBFD and UCT have contributed to enhance the levels and content of university education on international taxation with positive spillover effects in the African region, but also to increase the inclusive nature of research on international taxation.

As our Academic Chairman, Prof. Dr Pasquale Pistone puts it: "Her unparalleled experience as globally recognized top-notch expert of international taxation is also the source of pride for IBFD to support technical outstanding merits in line with our long-standing policy of promoting gender equality. From this perspective, Jennifer is an example for the entire academic community and a scholar with a remarkable curriculum."

IBFD is confident that many other academics from developing countries will look up to Jennifer as a model for striving to pursue excellence in their scientific work and make this world more inclusive and better.

Our Chief Executive Officer, Jan Maarten Slagter, adds, "I join my academic colleagues in welcoming Professor Roeleveld, who has been a member of the IBFD 'extended family' for years. I look forward to working with her!"

"It is a real honour to be the next IBFD Professor in Residence. As a long-serving academic in South Africa, I have been involved in the supervision of Master's and PhD students covering both South African and international taxation. South Africa has deep roots from Roman Dutch law and British law. Collaborating and sharing ideas with my European colleagues will be an exciting project," said Roeleveld.

"The Professor-in-Residence programme enables researchers from different jurisdictions to deepen their intellectual ties and extend their global knowledge. I am looking forward to this special experience and trust the project will be beneficial to all."

Jennifer Roeleveld's research focuses on international taxation. Her recent scholarship has examined issues around ceasing tax residency, mobility of work, taxpayers' rights and articles 27 and 17 of the IBFD GTTC.

Click hereto learn more about our 10th Professor in Residence and the projects between IBFD and UCT.

Contact information: Phil Windus, Senior Marketing Coordinator: p.windus@ibfd.org.

IBFD Academic

IBFDencourages academic excellence. It is our mission to stimulate the development of cross-border taxation and ensure the widest dissemination of tax knowledge. Our academic portfolio is key to achieving this goal. As the world's leading think tank in international tax law, we engage in an extensive range of academic activities. We work closely with universities and scientific institutions around the world to advance expertise and excellence throughout the international tax community

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a34962aa-874d-4690-9d63-17d6aae7ba93


© 2023 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.